Desmopressin treatment improves platelet function under flow in patients with postoperative bleeding

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 8, 2015, Pages 1503-1513

  Swieringa, F ^a   Lance M D ^b   Fuchs, B ^c   Feijge, M A H ^a   Solecka, B A ^c   Verheijen, L P J ^d   Hughes, K R ^a   van Oerle, R ^a   Deckmyn, H ^e   Kannicht, C ^c   Heemskerk, J W M ^a   van der Meijden, P E J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Octapharma RandD   (Germany)

^d DEPARTMENT OF SURGERY   (Netherlands)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Blood platelets; Deamino arginine vasopressin; Hemostasis; Platelet activation; Von Willebrand factor

Indexed keywords

DESMOPRESSIN; FIBRINOGEN; HEMOGLOBIN; PHOSPHATIDYLSERINE; PROTHROMBIN; THROMBIN; VON WILLEBRAND FACTOR; ARGIPRESSIN[1 DEAMINO]; HEMOSTATIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; THORAX SURGERY; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOELASTICITY; ADVERSE EFFECTS; BLOOD; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; DRUG EFFECTS; HEART SURGERY; METABOLISM; MIDDLE AGED; THROMBOCYTE; TREATMENT OUTCOME;

AGED; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CARDIAC SURGICAL PROCEDURES; DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLSERINES; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 84937935246     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13007     Document Type: Article

References (55)

1. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390-404.
2. Rugeri L, Beguin S, Hemker C, Bordet JC, Fleury R, Chatard B, Negrier C, Dargaud Y. Thrombin-generating capacity in patients with von Willebrand's disease. Haematologica 2007; 92: 1639-46.
3. Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93: 327-58.
4. Keuren JF, Ulrichts H, Feijge MA, Hamulyak K, Deckmyn H, Lindhout T, Heemskerk JW. Integrin aIIbb3 and shear-dependent action of glycoprotein Iba stimulate platelet-dependent thrombin formation in stirred plasma. J Lab Clin Med 2003; 141: 350-8.
5. Vanschoonbeek K, Feijge MA, van Kampen RJ, Kenis H, Hemker HC, Giesen PL, Heemskerk JW. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2: 476-84.
6. Keularts IM, Hamulyak K, Hemker HC, Beguin S. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb Haemost 2000; 84: 638-42.
7. Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional architecture of Weibel-Palade bodies. Blood 2011; 117: 5033-43.
8. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA 1987; 84: 1955-9.
9. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 1002-7.
10. Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 2014; 25: 206-16.
11. Schneider SW, Nuschele S, Wixforth A, Gorzelanny C, Alexander-Katz A, Netz RR, Schneider MF. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA 2007; 104: 7899-903.
12. Rybaltowski M, Suzuki Y, Mogami H, Chlebinska I, Brzoska T, Tanaka A, Banno F, Miyata T, Urano T. In vivo imaging analysis of the interaction between unusually large von Willebrand factor multimers and platelets on the surface of vascular wall. Pflugers Arch 2011; 461: 623-33.
13. De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood 2013; 121: 270-7.
14. Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 2006; 32: 514-21.
15. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia 2008; 14(Suppl. 5): 11-26.
16. Svensson PJ, Bergqvist PB, Juul KV, Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev 2014; 28: 95-102.
17. Wang JW, Bouwens EA, Pintao MC, Voorberg J, Safdar H, Valentijn KM, de Boer HC, Mertens K, Reitsma PH, Eikenboom J. Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease. Blood 2013; 121: 2762-72.
18. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873-81.
19. Schols SE, Lance MD, Feijge MA, Damoiseaux J, Marcus MA, Hamulyak K, Ten Cate H, Heemskerk JW, van Pampus EC. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 2010; 103: 318-28.
20. Davidson S. State of the art: how I manage coagulopathy in cardiac surgery patients. Br J Haematol 2014; 164: 779-89.
21. Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist JH. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 1999; 354: 106-10.
22. Weber CF, Dietrich W, Spannagl M, Hofstetter C, Jambor C. A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery. Anesth Analg 2010; 110: 702-7.
23. Pleym H, Stenseth R, Wahba A, Bjella L, Tromsdal A, Karevold A, Dale O. Prophylactic treatment with desmopressin does not reduce postoperative bleeding after coronary surgery in patients treated with aspirin before surgery. Anesth Analg 2004; 98: 578-84.
24. Cattaneo M. The use of desmopressin in open-heart surgery. Haemophilia 2008; 14(Suppl. 1): 40-7.
25. 12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 2005; 93: 1128-36.
26. Chen D, Tange JI, Meyers BJ, Pruthi RK, Nichols WL, Heit JA. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay. J Thromb Haemost 2011; 9: 1993-2002.
27. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
28. Schols SE, Feijge MA, Lance MD, Hamulyak K, ten Cate H, Heemskerk JW, van Pampus EC. Effects of plasma dilution on tissue-factor-induced thrombin generation and thromboelastography: partly compensating role of platelets. Transfusion 2008; 48: 2384-94.
29. Ninivaggi M, Feijge MA, Baaten CC, Kuiper GJ, Marcus MA, Ten Cate H, Lance MD, Heemskerk JW, van der Meijden PE. Principal roles of platelets and fibrinogen in whole-blood fibrin clot formation in dilutional coagulopathy determined by thromboelastometry. Thromb Haemost 2014; 111: 447-57.
30. van Kruchten R, Cosemans JM, Heemskerk JW. Measurement of whole blood thrombus formation using parallel-plate flow chambers: a practical guide. Platelets 2012; 23: 229-42.
31. Gilio K, van Kruchten R, Braun A, Berna-Erro A, Feijge MA, Stegner D, van der Meijden PE, Kuijpers MJ, Varga-Szabo D, Heemskerk JW, Nieswandt B. Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation. J Biol Chem 2010; 285: 23629-38.
32. Westein E, van der Meer AD, Kuijpers MJ, Frimat JP, van den Berg A, Heemskerk JW. Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner. Proc Natl Acad Sci USA 2013; 110: 1357-62.
33. Bonnefoy A, Romijn RA, Vandervoort PA, van Rompaey I, Vermylen J, Hoylaerts MF. von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen. J Thromb Haemost 2006; 4: 2151-61.
34. Vanhoorelbeke K, Depraetere H, Romijn RA, Huizinga EG, De Maeyer M, Deckmyn H. A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction. J Biol Chem 2003; 278: 37815-21.
35. Munnix IC, Gilio K, Siljander PR, Raynal N, Feijge MA, Hackeng TM, Deckmyn H, Smethurst PA, Farndale RW, Heemskerk JW. Collagen-mimetic peptides mediate flow-dependent thrombus formation by high- or low-affinity binding of integrin a2b1 and glycoprotein VI. J Thromb Haemost 2008; 6: 2132-42.
36. De Witt SM, Swieringa F, Cavill R, Lamers MM, van Kruchten R, Mastenbroek T, Baaten C, Coort S, Pugh N, Schulz A, Scharrer I, Jurk K, Zieger B, Clemetson KJ, Farndale RW, Heemskerk JW, Cosemans JM. Identification of platelet function defects by multi-parameter assessment of thrombus formation. Nat Commun 2014; 5: 4257.
37. Refaai MA, van Cott EM, Lukoszyk M, Hughes J, Eby CS. Loss of factor VIII and von Willebrand factor activities during cold storage of whole blood is reversed by rewarming. Lab Hematol 2006; 12: 99-102.
38. Panagiotopoulos I, Palatianos G, Michalopoulos A, Chatzigeorgiou A, Prapas S, Kamper EF. Alterations in biomarkers of endothelial function following on-pump coronary artery revascularization. J Clin Lab Anal 2010; 24: 389-98.
39. Beguin S, Keularts I, Al Dieri R, Bellucci S, Caen J, Hemker HC. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. J Thromb Haemost 2004; 2: 170-6.
40. Schols SE, van der Meijden PE, van Oerle R, Curvers J, Heemskerk JW, van Pampus EC. Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: relation to bleeding. Thromb Haemost 2008; 99: 64-70.
41. Fuchs B, de Witt S, Solecka BA, Kroning M, Obser T, Cosemans JM, Schneppenheim R, Heemskerk JW, Kannicht C. Distinct role of von Willebrand factor triplet bands in glycoprotein Ib-dependent platelet adhesion and thrombus formation under flow. Semin Thromb Hemost 2013; 39: 306-14.
42. Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, Mannucci PM. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol 1989; 73: 93-9.
43. Fischer BE, Kramer G, Mitterer A, Grillberger L, Reiter M, Mundt W, Dorner F, Eibl J. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res 1996; 84: 55-66.
44. Morowski M, Vögtle T, Kraft P, Kleinschnitz C, Stoll G, Nieswandt B. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood 2013; 121: 4938-47.
45. Batlle J, Lopez-Fernandez MF, Lopez-Borrasca A, Lopez-Berges C, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. Blood 1987; 70: 173-6.
46. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982; 59: 1272-8.
47. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682-9.
48. Bolliger D, Dell-Kuster S, Seeberger MD, Tanaka KA, Gregor M, Zenklusen U, Tsakiris DA, Filipovic M. Impact of loss of high-molecular-weight von Willebrand factor multimers on blood loss after aortic valve replacement. Br J Anaesth 2012; 108: 754-62.
49. Colucci G, Stutz M, Rochat S, Conte T, Pavicic M, Reusser M, Giabbani E, Huynh A, Thürlemann C, Keller P, Alberio L. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary function defects. Blood 2014; 123: 1905-16.
50. Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102: 4594-9.
51. Ranucci M, Nano G, Pazzaglia A, Bianchi P, Casana R, Tealdi DG. Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. J Cardiothorac Vasc Anesth 2007; 21: 851-4.
52. Ogawa S, Ohnishi T, Hosokawa K, Szlam F, Chen EP, Tanaka KA. Haemodilution-induced changes in coagulation and effects of haemostatic components under flow conditions. Br J Anaesth 2013; 111: 1013-23.
53. Calmer S, Ferkau A, Larmann J, Johanning K, Czaja E, Hagl C, Echtermeyer F, Goudeva L, Heuft HG, Theilmeier G. Desmopressin (DDAVP) improves recruitment of activated platelets to collagen but simultaneously increases platelet endothelial interactions in vitro. Platelets 2014; 25: 8-15.
54. Ozgonenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J 2007; 83: 159-63.
55. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briët E, Büller HR. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354: 1940-7.